Premium
EFFECT OF LABETALOL ON HUMAN PLATELET FUNCTION
Author(s) -
Anfossi Giovanni,
Trovati Mariella,
Lanzio Mario,
Mularoni Elena,
Massucco Paola,
Emanuelli Giorgio
Publication year - 1988
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.1988.tb01099.x
Subject(s) - labetalol , pharmacology , platelet , function (biology) , chemistry , medicine , biology , microbiology and biotechnology , blood pressure
SUMMARY 1. The effects of the α‐β‐adrenergic antagonist labetalol on the activation of human platelets by adrenaline and other aggregating stimuli have been investigated. 2. Labetalol inhibited platelet aggregation and secretion induced by collagen and the second phase of aggregation caused by ADP, platelet activating factor, adrenaline and ionophore A 23187 . Adrenaline‐induced platelet activation was inhibited by the lowest labetalol concentration. The response to Na arachidonate was minimally affected and the arachidonate‐induced thromboxane B 2 generation was only partially prevented. 3. The pre‐incubation with low concentration of ionophore A 23187 overcame labetalol's inhibition of collagen‐induced platelet aggregation. 4. Labetalol did not influence intraplatelet cyclic AMP levels. 5. The present investigation provided evidences that the modulation of human platelet function by labetalol could be related also to a decreased Ca 2+ availability.